enfuvirtide + optimized antiretroviral regimen

**Enfuvirtide + optimized antiretroviral regimen** is a combination therapy for **treatment-experienced HIV-1-infected patients** with evidence of HIV-1 replication despite ongoing therapy. Enfuvirtide is a biomimetic peptide and the first fusion inhibitor to be FDA-approved for this indication. It binds to the first heptad-repeat (HR1) in the gp41 subunit of HIV-1, blocking conformational changes required for viral–cell membrane fusion, and thus inhibits viral entry into CD4+ T cells. This regimen is used in conjunction with an individualized (“optimized”) background of other antiretrovirals, typically in patients with limited options due to resistance. Enfuvirtide is administered subcutaneously.

Brand names

Fuzeon

Other names

enfuvirtida